Bayer Aktiengesellschaft (VIE:BAYN)
Austria · Delayed Price · Currency is EUR | Market Cap | 41.60B +101.8% |
| Revenue (ttm) | 45.87B -1.9% |
| Net Income | -198.00M |
| EPS | -0.20 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 8.48 |
| Dividend | 0.11 (0.26%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 2,454 |
| Average Volume | 5,110 |
| Open | 42.64 |
| Previous Close | 42.81 |
| Day's Range | 42.12 - 42.73 |
| 52-Week Range | 18.66 - 49.70 |
| Beta | n/a |
| RSI | 43.05 |
| Earnings Date | Mar 4, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial StatementsNews
Bayer files lawsuit against Johnson & Johnson, Janssen Biotech
German pharmaceutical company Bayer said on Monday that it had filed a lawsuit in a New York court against Johnson & Johnson and Janssen Biotech Inc related to its Nubeqa prostate cancer drug.
Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that it has filed suit against Johnson & Johnson (J&J) and Janssen Biotech, Inc. in the United States District Court for the Southern District of...
Bayer, John Deere Further Integrate FieldView and Operations Center to Improve Customer Experience for 2026 Season
ST. LOUIS--(BUSINESS WIRE)--Bayer and John Deere today announced a new capability that simplifies how U.S. farmers and advisors move from agronomic decisions to precise execution in the field. Beginni...
Voyageur Pharmaceuticals Announces Collaboration with Bayer
Calgary, Alberta, Canada – TheNewswire – February 23, 2026 - Voyageur Pharmaceuticals Ltd. ( TSXV:VM) ( OTC Pink:VYYRF) (" Voyageur " or the " Company ") a Canadian developer of pharmaceutical-grade ...
Bayer proposes $7.25 billion Roundup settlement as Supreme Court case looms
A new $7.25 billion settlement between Bayer and a group of cancer patients could wrap up a huge wave of lawsuits against the company over allegations that it didn't warn consumers about cancer risks ...
Bayer: glyphosate shortages not expected outside the US after executive order
The U.S. President's executive order invoking the Defense Production Act to ensure U.S. supply of glyphosate underscores U.S. farmers' needs to have access to the herbicide, Bayer said on Thursday, ad...
Explainer: Will Bayer's proposed $7.25 billion Roundup deal bring legal closure?
Bayer's Monsanto unit has proposed a $7.25 billion nationwide class settlement to resolve both current and future lawsuits alleging that its Roundup weedkiller caused cancer, billing it as a long-awai...
Bayer retreats as investors sour on deal to settle Roundup litigation
Bayer's shares slumped as much as 9.2% on Wednesday, wiping out the previous day's gains, as investors questioned whether a proposed $7.25 billion settlement of cancer lawsuits over its Roundup weedki...
Bayer shares make this surprising move after $7.25 billion Roundup settlement accord
Bayer stock slumped on Wednesday as the German giant set a preliminary accord to cap litigation over its weedkiller Roundup.
Bayer falls 7% after proposing $7.25 billion settlement in Roundup case; European markets open higher
European stocks opened higher on Wednesday as investors monitor global market developments.
Bayer Aktiengesellschaft (BAYRY) Discusses Roundup Class Settlement Agreement and Implications for U.S. Glyphosate Litigation Transcript
Bayer Aktiengesellschaft (BAYRY) Discusses Roundup Class Settlement Agreement and Implications for U.S. Glyphosate Litigation Transcript
Bayer agrees to pay $7.25bn to settle Roundup weedkiller cancer lawsuits
Thousands of lawsuits accuse the agrochemical maker of failing to warn people that its weedkiller could cause cancer
Bayer Proposes New $7 Billion Plan to Settle Roundup Litigation
Company says settlement would address bulk of outstanding cases; the Supreme Court has agreed to hear Bayer's appeal to neutralize cancer claims.
Bayer CEO says Roundup settlement is important addition to Supreme Court case
Bayer's U.S. class settlement aimed at resolving current and future claims that Roundup weedkiller caused non‑Hodgkin lymphoma is an important addition to its Supreme Court case, Bayer CEO Bill Anders...
Bayer to make $10.5 bln push to settle roundup cases, Bloomberg reports
Bayer is planning to announce a $10.5 billion settlement push to settle current and future cancer lawsuits over its Roundup weedkiller, Bloomberg reported on Tuesday, citing people familiar with the p...
Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month
WHIPPANY, N.J.--(BUSINESS WIRE)--This American Heart Month, Bayer® Aspirin continues its mission to help people uncover the heart health risk factors they may not see with the launch of the Heart to H...
Oakmark International Strategy Q4 2025 Contributors And Detractors
Oakmark International Strategy portfolio's return was 4.93% (net) for the reporting period vs. MSCI World ex USA Index that returned 5.20% for the same period.
Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention Transcript
Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention Transcript
Bayer says its experimental blood thinner cuts risk of stroke recurrence by 26%
Bayer said on Thursday its experimental blood thinner cut the risk of stroke recurrence by 26% in a late-stage trial, in a fresh boost for CEO Bill Anderson's turnaround efforts.
Bayer's Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo
NEW ORLEANS--(BUSINESS WIRE)--Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibito...
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL' Campaign
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL' Campaign.
Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada
CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada's leadership in canola innovation by establishing a cutting-edge...
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
BERLIN--(BUSINESS WIRE)--Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two...
Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases
BERLIN & NASHVILLE, Tenn.--(BUSINESS WIRE)--Bayer and Vanderbilt University Medical Center (VUMC) today announced that they have entered a strategic five-year collaboration agreement to advance innova...
Supreme Court to hear Bayer's appeal to block thousands of Roundup weedkiller lawsuits
Bayer is arguing that consumers should not be able to sue it under state law for failing to warn that Roundup increases cancer risk because the Environmental Protection Agency has found no such risk a...